Negotiations among House Republicans have led to a compromise that would amend the American Health Care Act and the Association of Community Cancer Centers (ACCC) is concerned the amendment would undermine patient protections that are important for people with cancer, said Leah Ralph, director of health Policy at ACCC.
Negotiations among House Republicans have led to a compromise that would amend the American Health Care Act and the Association of Community Cancer Centers (ACCC) is concerned the amendment would undermine patient protections that are important for people with cancer, said Leah Ralph, director of health Policy at ACCC.
Transcript
What is the Association of Community Cancer Centers' take on the latest GOP proposals to reform healthcare in the United States?
We've seen in recent days, we have seen some negotiation between the heads of the Freedom Caucus and the moderate Republican group on the House side. And there is an effort to sort of find a path forward on the ACA repeal bill. The new amendment language that we've seen is really allowing states more flexibility to implement a lot of the insurance provisions in the ACA. So things like the essential health benefits, community health rating—it's allowing states to apply for waivers to allow insurers to opt out of those requirements.
ACCC's position has been on the ACA repeal bill that we really want to maintain those critical patient protections in the bill that seem particularly critical for cancer patients who, inherently with cancer you can't predict what your out-of-pocket costs will be, that you will be diagnosed with cancer, and that population really needs access to comprehensive, affordable insurance coverage. So there are some concerns, I think, with this new amendment that would change the underlying American Health Care Act that we've seen.
It's unclear at this point how many states would even apply for these waivers, what the impact would really be, but there are concerns abut underminding a lot of those patient protections that we gained in the Affordable Care Act.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More